NEW YORK and LONDON, October 14th, 2016
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment to its Board of Directors of Robert Ward. Mr. Ward, together with Donald Williams who was elected to the Board in June 2016, each bring over twenty-five years of pharmaceutical experience to the Board. Akari also announced that Mark Cohen, a director, has stepped down from the Board in order to serve as outside counsel to Akari on US intellectual property matters, and that David Byrne, who was appointed to the Board of Directors in April 2016, has been appointed to the compensation committee.
